Clinical Trial Update: BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BMS-986489 (Atigotatug) in combination with Nivolumab versus Durvalumab in limited-stage small cell lung cancer; trial is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Atigotatug (BMS-986489)
• Durvalumab (durvalumab)
• nivolumab (nivolumab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Limited Stage Small Cell Lung Cancer | Phase 2 | Status: RECRUITING